"Better Therapeutics continued its strong momentum in the third quarter, with the completion of the BT-001 pivotal clinical trial and acceptance of its de novo classification request to the U.S. Food and Drug Administration seeking marketing authorization for BT-001," stated Frank Karbe, President and CEO of Better Therapeutics. "We believe the publication of our trial results in a leading peer-reviewed journal further highlights the quality of our data and novelty of our approach as does the encouraging feedback we have received from our payer interactions to date. Additionally, we significantly advanced our financing discussions, and our team is laser-focused on preparing for the potential launch of our first-in-class prescription digital therapeutic for the treatment of type 2 diabetes (T2D) in adults next year, if authorized by FDA."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTTX:
